ARGX 111

Drug Profile

ARGX 111

Alternative Names: Anti-cMet SIMPLE Antibody; ARGX-111

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator arGEN-X
  • Developer argenx
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 17 Feb 2016 Phase-I clinical trials in Solid tumours in South Korea (Parenteral)
  • 18 Feb 2015 arGEN-X in-licenses GS Xceed™ System Technology from Lonza
  • 15 Apr 2014 ARGX 111 remains available for licensing as of 15 April 2014. http://www.argen-x.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top